Clinical Trials
91 trialsDC15-MM-01
Cartesian Therapeutics
PROACT
Washington University School of Medicine
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Thomas Jefferson University
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Thomas Jefferson University
ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma
Celgene
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
Seagen Inc.
Descartes-25 in Relapsed/Refractory Multiple Myeloma
Cartesian Therapeutics
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
Servier
Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
Columbia University
A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
Taiho Oncology, Inc.
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Pfizer
ClaSPd
Weill Medical College of Cornell University
FT538 in Subjects With Advanced Hematologic Malignancies
Fate Therapeutics
Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation
Eastern Cooperative Oncology Group
PET Imaging of Subjects Using 124I-PU-AD
Samus Therapeutics, Inc.
A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Hackensack Meridian Health
PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma
Herlev Hospital
AntiCD-66
University of Southampton
Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
Icahn School of Medicine at Mount Sinai
Arsenic Trioxide in Treating Patients With Multiple Myeloma
CTI BioPharma
Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma
CTI BioPharma
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer
M.D. Anderson Cancer Center
DMV
University of California, San Francisco
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Masonic Cancer Center, University of Minnesota
Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma
NYU Langone Health
A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
Masonic Cancer Center, University of Minnesota
Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
M.D. Anderson Cancer Center
Positron Emission Tomography (PET) Imaging Studies With NIS Reporter
Mayo Clinic
Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)
M.D. Anderson Cancer Center
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Barbara Ann Karmanos Cancer Institute
Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
PrE1003
PrECOG, LLC.
DexTR
Weill Medical College of Cornell University
Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant
M.D. Anderson Cancer Center
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
NYU Langone Health
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Pilot Study of Multi-Modality Imaging in Patients With Hematologic Malignancies
Masonic Cancer Center, University of Minnesota
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases
Masonic Cancer Center, University of Minnesota
Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma
Masonic Cancer Center, University of Minnesota
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Masonic Cancer Center, University of Minnesota
CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients
University of Arkansas
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
OHSU Knight Cancer Institute
Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies
Milton S. Hershey Medical Center
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
Fred Hutchinson Cancer Center